Beckman Coulter Signs Health System Agreements Totaling $31.5 Million in Second Quarter 2001.

Business Editors & Health/Medical Writers

FULLERTON, Calif.--(BUSINESS WIRE)--July 24, 2001

Beckman Coulter, Inc. (NYSE:BEC) announced today it signed eight agreements valued at approximately $31.5 million with integrated health networks (IHN) and integrated health delivery systems (IHDS) during its second quarter, which ended June 30, 2001.

Under the terms of the five-year agreements, which are for 100-percent compliance on the respective contracted products, Beckman Coulter will provide diagnostic laboratory instrument systems, consumables and service to nearly 50 hospitals and reference laboratories across the United States. The agreements include the following:

-- $10-million contract with Diagnostic Laboratory Services in Honolulu for
automation, chemistry and immunodiagnostic products;

-- $7-million contract with Veterans Integrated Service Network 8 in Tampa,
Fla., for hematology and immunodiagnostic products; and

-- $6-million contract with Baptist Healthcare System in Jacksonville, Fla.,
for immunodiagnostic products.

Five agreements totaling $8.5 million were signed with Virtua Health in Vorhees, N.J.; Meridian Health in Wall, N.J.; South Jersey Hospital System in Bridgeton, N.J.; Cox Health Systems in Springfield, Mo.; and Centrex Clinical Laboratories in Utica, N.Y. These contracts include purchase orders for hematology, immunodiagnostic and hemostasis products.

"To date, we have signed health network and delivery system contracts valued at $71 million during the first half of this year," said Joseph A. Brogan, Beckman Coulter senior director of integrated health care networks, diagnostics in North America. "This increase is due to a higher number of contracts signed during the first half of the year as well as more agreements for multiple products lines."

Beckman Coulter, headquartered in Fullerton, Calif., is a leading provider of instrument systems and complementary products that simplify and automate processes in life science and clinical laboratories. The company's products are used throughout the world in all phases of the battle against disease, from pioneering medical research and drug discovery to diagnostic testing that aids in patient treatment. Annual sales for the company totaled $1.89 billion in 2000, with approximately half of this amount generated outside the United States. For more information, visit www.beckmancoulter.com.